glp-1 shortage guidance New on the use of GLP-1-based drugs in people with type 1 diabetes (T1D), due to be published later this year, will address the safety and optimal use of these medications GLP-1 Receptor Agonist Shortage: Challenges
Description
Masayasu Kojima, Kurume University, Japan Updates Copyright 2017 Lindqvist, Shcherbina, Fischer and Wierup
,
doi: 10.1164/rccm.202004-0993OC
the molecules are too big and unstable to get through the skin barrier
These outcomes highlight a dual benefit of the medication, addressing both obesity and diabetes effectively
Funding KVRH, KB, DW, and HSN acknowledge funding from the Novo Nordisk Foundation (NNF21OC0069257 and NNF220C0077221) and the AP Moller Foundation
